Context Therapeutics Inc. (6K9.F)
| Previous Close | 1.9580 |
| Open | 1.9560 |
| Bid | 1.8580 x N/A |
| Ask | 1.9140 x N/A |
| Day's Range | 1.9560 - 1.9720 |
| 52 Week Range | 1.9560 - 8.9860 |
| Volume | |
| Avg. Volume | 900 |
| Market Cap | 22.353M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.4030 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Context Therapeutics® Strengthens Research & Development Team
Company names Christopher Beck as SVP, Operations and Mark Fletcher, Ph.D., as VP, R&DPHILADELPHIA, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, today announced the appointments of Christopher Beck as SVP of Operations and Mark Fletcher, Ph.D., as VP of R&D. Context also announced the planned retirement of its current
- GlobeNewswire
Context Therapeutics® to Participate in Two January 2022 Investor Conferences
PHILADELPHIA, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, today announced that Chief Executive Officer Martin Lehr will participate virtually in two investor conferences in January 2022. Details of the events are as follows: Biotech Showcase™ 2022: The company’s presentation will be available for on-demand viewing dur
- GlobeNewswire
Context Therapeutics® Announces Positive Data from ONA-XR in Early Breast Cancer at 2021 San Antonio Breast Cancer Symposium
Data demonstrated ONA-XR decreased proliferation in tumors with high PR+ at baseline in early breast cancer Two additional metastatic breast cancer clinical trials in progress also presented PHILADELPHIA, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, today announced that data from the window-of-opportunity clinical trial of onapristone extended rel
